Markets
Stocks
Mutual Funds & ETF's
Sectors
Tools
Overview
Market News
Currencies
International
Search InvestCenter
Recent Quotes
My Watchlist
Top Indices
My Portfolio

CRISPR Therapeutics AG - Common Shares (NQ:CRSP)

34.19 +1.05 (+3.17%)
Streaming Delayed Price Updated: 4:00 PM EDT, Apr 2, 2025 Add to My Watchlist
Quote
Overview Detailed Quote Charting Historical Prices
News
All News News Headlines Press Releases
Research
Quarterly Reports Insider Filings Other Filings

All News about CRISPR Therapeutics AG - Common Shares

< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
31 32 Next >
3 Healthcare Stocks to Make You the Millionaire Next Door: 2024 Edition
Healthcare stocks tend to be more mature and reliable, but a handful of innovators offer massive long-term upside. 
Via InvestorPlace
Better Risky Investment: Bluebird Bio vs. Shiba Inu
Few investors dare to tread where the ice is known to be very thin. 
Via The Motley Fool
3 Biotech Stocks Set for Breakthroughs in 2024
With groundbreaking advancements in new medicine and science, 2024 holds a promising future for these biotech stocks. 
Via InvestorPlace
2 gene-editing stocks reshaping hereditary disease treatments
Gene-editing companies are making headlines for the potential to reshape the future of healthcare and the treatment of hereditary diseases. The U.S. Federal 
Via MarketBeat
Here's How Much $100 Invested In CRISPR Therapeutics 5 Years Ago Would Be Worth Today
Via Benzinga
Could CRISPR Therapeutics Stock Help You Become a Millionaire?
There are plenty of reasons to be optimistic about CRISPR's future. 
Via The Motley Fool
3 No-Brainer Growth Stocks to Buy for Less Than $100
These businesses have promising futures and make for great investment options today. 
Via The Motley Fool
1 Cathie Wood Stock Worth Buying Hand Over Fist in 2024
Ark Invest holds a hefty position in this gene-editing stock. Risk-tolerant investors may want to take a page from the fund's playbook on this name. 
Via The Motley Fool
2 Gene-Editing Stocks That Might Be the Next CRISPR Therapeutics
Curing rare inherited illnesses could be a lucrative business model. 
Via The Motley Fool
2023 in Review: Nvidia, Interest Rates, Taylor Swift
And a little bit of real estate insight. 
Via The Motley Fool
3 Stocks That Could Be Monster Winners in 2024
Don't be surprised if these three stocks take off in the new year. 
Via The Motley Fool
AI and Automation Leaders for 2024: 7 Stocks to Stay Ahead of the Robot Uprising
With the robotics revolution taking over multiple industries, investors have options. 
Via InvestorPlace
Topics Artificial Intelligence
Exposures Artificial Intelligence
CRISPR Therapeutics sets sights on gene-editing cures for disease
On Dec. 8, 2023, Vertex Pharmaceuticals Inc. (NASDAQ: VRTX) announced the U.S. FDA approved its sickle-cell disease (SCD) treatment, Casgevy, for 
Via MarketBeat
Exposures Product Safety
3 Top Stocks to Buy Hand Over Fist Before the End of 2023
These are ideal stocks to buy sooner rather than later. 
Via The Motley Fool
3 Healthcare Technology Stocks to Improve Lives in 2024
Healthcare technology is one of 2024's top investment trends, and investors looking for long-term upside should check out these top stocks. 
Via InvestorPlace
1 Green Flag and 1 Red Flag for Bluebird Bio Stock
The stock has been in the news lately. 
Via The Motley Fool
Cathie Wood Predicts Deflation In 2024, More AI And Tech Optimism — And Rate Cuts
Cathie Wood believes deflation in 2024, aggressive rate cuts and technological progress will drive expansion. 
Via Benzinga
Topics Artificial Intelligence Economy
Exposures Artificial Intelligence Interest Rates
3 Money-Saving Tricks for Investing in Biotech Stocks in 2024
Doing a little math and doing a little extra research can make a big difference. 
Via The Motley Fool
I'm Begging You to Buy Stocks Before January -- Here's Why
Some studies have shown a pattern of market gains in the month of January. 
Via The Motley Fool
Up More Than 60% in 2023, Is It Too Late to Buy This Soaring Biotech Stock?
The FDA's recent approval of CRISPR Therapeutics' first therapy is a step in the right direction. 
Via The Motley Fool
Exposures Product Safety
6 Words That Explain Why CRISPR Stock Isn't Soaring Despite the Recent FDA Approval for Its Gene-Editing Therapy
Should you buy CRISPR's stock on the dip? 
Via The Motley Fool
Exposures Product Safety
Better Bull Market Buy: CRISPR Therapeutics vs. Pfizer Stock
These stocks are currently going in different directions, but both could go up in a new bull market. 
Via The Motley Fool
Is Vertex Pharmaceuticals Sitting on a Gold Mine?
Vertex shares have climbed about 40% this year. 
Via The Motley Fool
CRSP Stock Alert: CRISPR Therapeutics Is Losing Its Medical Chief
The fate of Crispr and CRSP stock will be determined by the success of other drugs in the company's pipeline rather than Casgevy. 
Via InvestorPlace
3 Reasons to Buy CRISPR Therapeutics Stock Like There's No Tomorrow
CRISPR Therapeutics stock has increased in the double digits this year. 
Via The Motley Fool
3 Genomics Stocks to Unlock the Future of Medicine
Genomics stocks stand to surge in 2024 after the FDA approved the nation's first gene-editing therapeutic for clinical use. 
Via InvestorPlace
Exposures Product Safety
Better Growth Stock: Archer Aviation or Prime Medicine?
Which of these innovation-themed growth stocks is the better buy? 
Via The Motley Fool
3 Healthcare Stocks That Could Help Make You a Millionaire
These stocks each have reached an important turning point that could signal growth ahead. 
Via The Motley Fool
2 Stocks Profiting From Unstoppable Trends That Could Make You Rich
It's important to choose companies involved in trends that have long-term potential. 
Via The Motley Fool
2 Stocks That Could Turn $1,000 Into $3,500 in 10 Years
These businesses are exciting and can also lead to outsized long-term returns. 
Via The Motley Fool
< Previous 1 2
...
5 6 7 8 9 10 11 12 13
...
31 32 Next >
Stock Quote API & Stock News API supplied by www.cloudquote.io
Quotes delayed at least 20 minutes.
By accessing this page, you agree to the following
Privacy Policy and Terms and Conditions.